Magnaspartate 243 mg powder for oral solution

*
Pharmacy Only: Prescription
  • Company:

    Kora Healthcare
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may be renewed (B)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 15 November 2024

File name

ie-spc-clean.pdf

Reasons for updating

  • Change to product name

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Given Magnence 243 mg powder for oral solution is not on the Irish market and Magnence joint pack is planned for Q3 2025, we are updating to previous version to avoid confusions with name change

Updated on 15 November 2024

File name

ie-pl-clean.pdf

Reasons for updating

  • Change to product name

Free text change information supplied by the pharmaceutical company

Given Magnence 243 mg powder for oral solution is not on the Irish market and Magnence joint pack is planned for Q3 2025, we re updating to the previous version to avoid confusion with product name

Updated on 01 August 2024

File name

ie-spc-clean.pdf

Reasons for updating

  • Change to product name

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 01 August 2024

File name

ie-pl-clean.pdf

Reasons for updating

  • Change to name of medicinal product

Updated on 15 May 2024

File name

ie-spc-Nov2022-magnaspartate.pdf

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 May 2024

File name

ie-pl-Jul2022-magnaspartate.pdf

Reasons for updating

  • Change to date of revision

Updated on 15 August 2022

File name

Magnaspartate-spc.pdf

Reasons for updating

  • Change to MA holder contact details

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 August 2022

File name

Magnaspartate-PIL.pdf

Reasons for updating

  • Change to MA holder contact details

Updated on 31 January 2022

File name

SPC-Magnaspartate-Licence_PA1748-002-001.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 31 January 2022

File name

PIL-Magnaspartate-Licence_PA1748-002-001.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 4 - how to report a side effect

Updated on 22 July 2020

File name

ie-spc-revised July 2020.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 22 July 2020

File name

ie-pl-revised July 2020.pdf

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 30 April 2020

File name

ie-spc-revised April 2020.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 30 April 2020

File name

ie-pl-revised March 2020.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Change of trade or active ingredient name

Updated on 29 April 2019

File name

ie-PIL.pdf

Reasons for updating

  • New PIL for new product

Updated on 29 April 2019

File name

ie-spc.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)